Edition:
United States

Apricus Biosciences Inc (APRI.OQ)

APRI.OQ on NASDAQ Stock Exchange Capital Market

1.27USD
2 Dec 2016
Change (% chg)

$0.01 (+0.79%)
Prev Close
$1.26
Open
$1.36
Day's High
$1.36
Day's Low
$1.27
Volume
6,838
Avg. Vol
13,796
52-wk High
$15.40
52-wk Low
$1.26

APRI.OQ

Chart for APRI.OQ

About

Apricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company's drug delivery technology is a permeation enhancer called NexACT. The... (more)

Overall

Beta: 0.22
Market Cap(Mil.): $12.61
Shares Outstanding(Mil.): 7.73
Dividend: --
Yield (%): --

Financials

  APRI.OQ Industry Sector
P/E (TTM): -- 29.13 29.87
EPS (TTM): -1.65 -- --
ROI: -- 15.56 14.95
ROE: -- 16.69 16.29

BRIEF-Apricus intends to re-submit Vitaros NDA as soon as possible in 2017

* Received feedback in response to its previously announced Type B meeting request to U.S. Food and Drug Administration

Nov 18 2016

BRIEF-Apricus Biosciences posts Q3 loss per share $0.19

* Apricus Biosciences provides corporate update and third quarter financial results

Nov 08 2016

BRIEF-Apricus Biosciences announces 1-for-10 reverse stock split

* Apricus Biosciences Inc - reverse stock split will be effective at 5:00 p.m. Pacific time on October 21, 2016 Source text for Eikon: Further company coverage: ;))

Oct 20 2016

BRIEF-Anson Funds Management LP reports a passive stake of 7 percent in Apricus Biosciences

* Anson Funds Management LP reports a passive stake of percent in Apricus Biosciences Inc as of September 28, 2016 - SEC filing Source text for Eikon: Further company coverage:

Oct 07 2016

BRIEF-Apricus Biosciences and certain investors mutually agreed to terminate certain securities purchase agreement

* On Sept 27, co and certain investors mutually agreed to terminate certain securities purchase agreement, dated Sept 22

Sep 28 2016

BRIEF-Apricus Biosciences to issue about 13.1 mln shares at $0.35 per share

* Apricus Biosciences announces $4.6 million registered direct offering

Sep 23 2016

BRIEF-Apricus biosciences announces completion of transfer of marketing authorizations

* Apricus Biosciences announces completion of transfer of marketing authorizations for Vitaros in Finland and Denmark to Ferring Pharmaceuticals

Sep 20 2016

BRIEF-Apricus Biosciences announces approval of Vitaros for the treatment of Erectile Dysfunction in Argentina

* Apricus Biosciences announces approval of Vitaros for the treatment of erectile dysfunction in Argentina Source text for Eikon: Further company coverage:

Sep 08 2016

BRIEF-Apricus Biosciences announces launch of novel topical treatment

* Apricus Biosciences announces the launch of its novel topical treatment for erectile dysfunction in Portugal, Ireland and Poland by Recordati Source text for Eikon: Further company coverage:

Sep 06 2016

BRIEF-Apricus Biosciences says gets $4.5 mln in upfront payments from Ferring

* Company's partner in United Kingdom, has received United Kingdom marketing authorization for Vitaros

Aug 15 2016

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $31.63 +0.17
GlaxoSmithKline plc (GSK.L) 1,467.00p -1.50
Eli Lilly and Co (LLY.N) $67.71 +1.74
Abbott Laboratories (ABT.N) $37.90 +0.30

Earnings vs. Estimates